Skip to main content
Premium Trial:

Request an Annual Quote

Aetna, Cigna, UnitedHealthcare to Cover Agendia's MammaPrint

NEW YORK (GenomeWeb) – Agendia announced today that its MammaPrint 70-gene signature breast cancer recurrence risk test has received positive coverage decisions from Aetna, Cigna, and UnitedHealthcare.

According to Agendia, the three insurers cover more than 85 million people in the US and internationally.

"The positive coverage decisions by these major healthcare insurers echo the rapidly increasing adoption of MammaPrint among US physicians who recognize the value of the test to personalize and, in many cases, de-escalate treatment for early breast cancer," Agendia Chief Medical Officer William Audeh said in a statement. "MammaPrint provides physicians with a binary low risk or high risk of recurrence result that has considerable quality of life and cost-saving implications."

Last year, Blue Shield of California and First Coast Service Options — the Medicare contractor for Florida, Puerto Rico, and the Virgin Islands — began covering MammaPrint. Also in 2017, the American Society of Clinical Oncology published revised early-stage breast cancer guidelines that feature a focused update recommending MammaPrint for guiding treatment decisions in early-stage breast cancer patients with one-to-three positive lymph nodes.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more